# Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

> **NCT04179396** · PHASE1 · COMPLETED · sponsor: **pharmaand GmbH** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Enzalutamide
- **DRUG:** Abiraterone

## Key facts

- **NCT ID:** NCT04179396
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-05
- **Primary completion:** 2021-11-25
- **Final completion:** 2023-01-18
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179396, "Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04179396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*